
NASDAQHealthcareBiotechnology
أحدث البيانات المتاحة
1.41 US$
+0.05 US$ · +3.68%
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
الإغلاق السابق
1.41 US$
+0.05 US$ · +3.68%
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
نطاق اليوم
السعر الحالي 1.41 US$
نطاق 52 أسبوعًا
السعر الحالي 1.41 US$
تستخدم الأوقات اليومية المنطقة الزمنية ET. قد تتأخر بيانات السوق.
نقاط GoAI
احتفاظ
تقييم
77
أقل من القيمة
المشاعر
28
هبوطي
المخاطر
76
مخاطر مرتفعة
الزخم
56
محايد
بحث كامل عن GoAI
تابع للاطلاع على أدلة ومحفزات ومخاطر أعمق.
Codexis, Inc. is a biotechnology firm dedicated to the discovery, development, and commercialization of enzymes and other protein-based solutions. Its diverse portfolio encompasses advanced biocatalyst products and related services, specialized chemical intermediates vital for subsequent processing steps, and proprietary biocatalyst panels and kits that empower clients to conduct effective chemistry screening. The company also extends its expertise through biocatalyst screening and sophisticated protein engineering services. Central to its operations is the proprietary CodeEvolver protein engineering technology platform. This innovative platform is instrumental in crafting and delivering high-performance biocatalysts capable of driving chemical transformations, thereby significantly enhancing the efficiency and productivity of manufacturing processes. Beyond industrial applications, the CodeEvolver platform is also leveraged for identifying novel biotherapeutic drug candidates for targeted human diseases, as well as for developing enzymes essential for molecular biology research and in vitro diagnostic applications. Primarily serving pharmaceutical manufacturers, Codexis distributes its products through its dedicated direct sales and business development teams across the United States and Europe. Established in 2002, the company maintains its headquarters in Redwood City, California.
نطاق اليوم
السعر الحالي 1.41 US$
نطاق 52 أسبوعًا
السعر الحالي 1.41 US$
الربحية كنسبة مئوية من الإيرادات المعلنة.
الإيرادات
الدخل التشغيلي
صافي الدخل
| البند (USD) | السنة المالية 2025 | السنة المالية 2024 | السنة المالية 2023 | السنة المالية 2022 | السنة المالية 2021 |
|---|---|---|---|---|---|
| الإيرادات | 70.39 مليون USD | 59.35 مليون USD | 70.14 مليون USD | 138.59 مليون USD | 104.75 مليون USD |
| تكلفة البضاعة المباعة | 9.34 مليون USD | 16.29 مليون USD | 12.81 مليون USD | 38.03 مليون USD | 22.21 مليون USD |
| الربح الإجمالي | 61.05 مليون USD | 43.06 مليون USD | 57.33 مليون USD | 100.56 مليون USD | 82.55 مليون USD |
| البحث والتطوير | 52.31 مليون USD | 46.26 مليون USD | 58.89 مليون USD | 80.1 مليون USD | 55.92 مليون USD |
| مصاريف البيع والمصاريف العمومية والإدارية | 47.07 مليون USD | 55.15 مليون USD | 53.25 مليون USD | 52.17 مليون USD | 49.32 مليون USD |
| نفقات التشغيل | 99.38 مليون USD | 101.58 مليون USD | 125.4 مليون USD | 135.44 مليون USD | 105.24 مليون USD |
| دخل الفوائد | 2.63 مليون USD | 3.67 مليون USD | 4.17 مليون USD | 1.44 مليون USD | 459 ألف USD |
| مصاريف الفوائد | 4.81 مليون USD | — | — | — | — |
| الاستهلاك والإطفاء | 5.25 مليون USD | 4.95 مليون USD | 9.92 مليون USD | 10.25 مليون USD | 5.95 مليون USD |
| الدخل التشغيلي | −38.33 مليون USD | −58.52 مليون USD | −68.07 مليون USD | −34.88 مليون USD | −22.7 مليون USD |
| صافي الدخل | −43.97 مليون USD | −65.28 مليون USD | −76.24 مليون USD | −33.59 مليون USD | −21.28 مليون USD |
تم تحديث حقائق الشركة 11 أكتوبر 2026.
النتائج المعلنة مع توقعات الإجماع المتاحة.
النتائج المعلنة مع توقعات الإجماع المتاحة.
قد تتغير تقديرات المحللين الخارجيين، وهي ليست توصيات من GoAI.
متوسط الهدف
8.00 US$
ارتفاع محتمل بنسبة 467.38%صناديق متداولة تفصح عن تعرضها لهذا السهم.
Vanguard Morningstar Total Stock Market ETFVTI5.23 مليون0.00%2.3 ترليون USD0.03%381.94 US$+0.63%
iShares Russell 2000 ETFIWM3.5 مليون0.00%78.74 مليار USD0.19%278.94 US$+0.49%
Vanguard Extended Market ETFVXF1.54 مليون0.00%95.4 مليار USD0.05%235 US$+0.80%
iShares Russell 2000 Growth ETFIWO1.09 مليون0.01%13.92 مليار USD0.24%356.78 US$+0.94%
iShares Biotechnology ETFIBB1.07 مليون0.01%10.82 مليار USD0.44%206.49 US$+3.00%
Vanguard Russell 2000 ETFVTWO846.59 ألف0.00%18 مليار USD0.06%112.66 US$+0.50%
iShares Micro-Cap ETFIWC433.98 ألف0.03%1.32 مليار USD0.60%183 US$+0.11%
Fidelity Enhanced Small Cap ETFFESM243.87 ألف—6.41 مليار USD0.28%45.46 US$+0.46%
Vanguard Morningstar Total Stock Market ETFVTI
iShares Russell 2000 ETFIWM
Vanguard Extended Market ETFVXF
iShares Russell 2000 Growth ETFIWO
iShares Biotechnology ETFIBB
Vanguard Russell 2000 ETFVTWO
iShares Micro-Cap ETFIWC
Fidelity Enhanced Small Cap ETFFESMالمحتوى المُنشأ بالذكاء الاصطناعي وبيانات السوق المتأخرة لأغراض معلوماتية وتعليمية فقط، ولا تُعد نصيحة استثمارية.